Education
About Us
Working with TipRanks
Follow Us
4SC AG (GB:0R6U)
LSE:0R6U
0R6U Stock Chart & Stats
€7.82
€0.00(0.00%)
At close: 4:00 PM EST
€7.82
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€7.83 - €7.83
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€6.13M
Enterprise Value€1.11M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Oct 17, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding10,906,089
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
4SC AG News
0R6U FAQ
What was 4SC AG’s price range in the past 12 months?
4SC AG lowest share price was €7.83 and its highest was €7.83 in the past 12 months.
What is 4SC AG’s market cap?
4SC AG’s market cap is €6.13M.
When is 4SC AG’s upcoming earnings report date?
4SC AG’s upcoming earnings report date is Oct 17, 2025 which is 56 days ago.
How were 4SC AG’s earnings last quarter?
Currently, no data Available
Is 4SC AG overvalued?
According to Wall Street analysts 4SC AG’s price is currently Overvalued.
Does 4SC AG pay dividends?
4SC AG does not currently pay dividends.
What is 4SC AG’s EPS estimate?
4SC AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 4SC AG have?
4SC AG has 10,906,089 shares outstanding.
What happened to 4SC AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of 4SC AG?
Currently, no hedge funds are holding shares in GB:0R6U
4SC AG Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.00%
12-Months-Change
Fundamentals
Return on Equity
-288.87%
Trailing 12-Months
Asset Growth
7.49%
Trailing 12-Months
Company Description
4SC AG
4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. The company's pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development: resminostat and domatinostat.
Technical Analysis
Biotest
―
B.R.A.I.N. Biotechnology Research and Information Network
―
Heidelberg Pharma AG
―
CytoTools AG
―
Formycon AG
―